The investment strategy has always been bad. People, like you, who do not understand the strategy are the issue.
HER-Vaxx was tried and tested in populations that can't afford Herceptin at statistical power below industry standards.
This means small TAM and low $ per dose, with data that is not transferrable to the competitive global market.
This means that the price increase from 8c to 60c was a miracle and most people lacked the understanding of data and strategy, which is why I was telling everyone to sell.
Oh, you thought Merck dropped HER-Vaxx because they wanted a deal? lol.
CF33 was bought because HER-Vaxx was failing.
Professor Yuman Fong, the inventor of CF33, sold 33M shares before CF33 was dosed in a single patient.
No skin in the game.
Management have not updated the market in an open-label trial for >6-months now because the drug is failing badly.
All you have to do is look at ATX to see the lack of limitations for reporting of clinical data in open label trials.
Azer-cel was bought because all of the CF33 programs are expected to fail.
And, so, the cycle continues.
Industry news, page-2035
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
0.010(0.65%) |
Mkt cap ! $265.8M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.56 | $1.51 | $95.69K | 62.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3015 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 4018 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |